| Literature DB >> 21371458 |
Michele M Kosiewicz1, Dominick L Auci, Paolo Fagone, Katia Mangano, Salvatore Caponnetto, Colleen F Tucker, Nabeel Azeem, Steven K White, James M Frincke, Christopher L Reading, Ferdinando Nicoletti.
Abstract
5-Androstene-3β,7β,17β-triol (AET) is a naturally occurring anti-inflammatory adrenal steroid that limits acute and chronic inflammation. HE3286 (17α-ethynyl-5-androstene-3β,7β,17β-triol) is a synthetic derivative of AET with improved pharmaceutical properties and efficacy in some animal models of autoimmunity. Here, daily oral doses of HE3286 led to a suppression of spontaneous autoimmune diabetes in the non-obese diabetic mouse model of type 1 diabetes mellitus when administered either shortly before or after the first incidence of disease onset. Efficacy was associated with reduced insulitis and a suppression of the pathogenic T helper cell type 1 and type 17 phenotypes in peripheral lymphoid organs. These results demonstrate that daily oral treatment with HE3286 administrated relatively late in the destructive autoimmune process led to a suppression of type 1 diabetes mellitus onset and of the pathological inflammatory status, supporting its clinical evaluation in type 1 diabetes mellitus subjects.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21371458 DOI: 10.1016/j.ejphar.2011.02.016
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432